RT Journal
A1 Zaccarelli E, Tomao S, Codacci-Pisanelli G
T1 KRas genotypes and outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab
JF JAMA
JO JAMA
YR 2011
FD February 9
VO 305
IS 6
SP 564
OP 566
DO 10.1001/jama.2011.87
UL http://dx.doi.org/10.1001/jama.2011.87
AB 
To the Editor:  The study by Dr De Roock and colleagues1 suggests that all KRAS mutations in patients with metastatic colorectal cancer are not the same and that they interact differently with anti-epidermal growth factor receptor monoclonal antibodies. Did the authors analyze, in cancers harboring the p.G13D mutation, the mutational status of BRAF and other genetic elements that determine the activity of anti-epidermal growth factor receptor monoclonal antibodies in such tumors that are not mutated for KRAS?2